The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
基本信息
- 批准号:8127100
- 负责人:
- 金额:$ 5.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-04 至 2014-07-03
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAgeAgricultureAnimalsAntigensArchaeaAreaBacteriaBiological AssayBiological MarkersBirthCellsCessation of lifeChildChildhoodCholera ToxinCommunitiesDNADefectDevelopmentDietDiet MonitoringEndotoxinsEnteralEnzyme-Linked Immunosorbent AssayExcretory functionExhibitsFailureFamilyFemaleFetal MalnutritionFoodFreezingGene ExpressionGenesGerm-FreeGleanGnotobioticHarvestHistologyHumanImmuneImmune systemImmunoglobulin AImmunoglobulin GInfantInfectionInterventionIntestinesKwashiorkorLactuloseLeadLifeLinkLongitudinal StudiesMacronutrients NutritionMalawiMalnutritionMannitolMessenger RNAMetabolicMetagenomicsMethodsMicronutrientsModelingMonitorMonozygotic TwinningMonozygotic twinsMorbidity - disease rateMorphologyMothersMucosal Immune ResponsesMucosal ImmunityMusNational Research Service AwardsNeurodevelopmental DeficitNutrientNutritionalNutritional SupportNutritional statusOralOvalbuminPartner in relationshipPathogenesisPatternPhysiologicalPneumoniaPopulationPredispositionPregnancyProtocols documentationRNARecurrenceRelative (related person)Ribosomal RNARoleSamplingSeriesSerumShapesShotgunsSiblingsStructureSurveysTestingTherapeuticTherapeutic UsesTimeTranslationsTransplantationTwin Multiple BirthVaccinatedVaccinationVaccine DesignVaccinesWeaningWithdrawalabsorptionageddesigndisorder riskexpectationfeedingfunctional genomicsglobal healthgut microbiotaimmune functioninsightkillingsmembermicrobialmicrobial communitymicrobiomemicronutrient deficiencymortalitymouse modelmucosal vaccinationoffspringpostnatalpregnantpuprRNA Genesresearch studyresponsetransmission process
项目摘要
DESCRIPTION (provided by applicant): Malnutrition kills millions of children worldwide every year. Much of their morbidity and mortality is a result of infections, including those caused by enteropathogens. Efforts to stop these infections have been limited in some populations by unexplained vaccine failures. I hypothesize that there is an interrelationship between malnutrition, the gut microbiome, and the immune system that is causally linked with vaccine responsiveness and that these interrelationships can be informatively probed using 'humanized' gnotobiotic mice. Our lab is conducting longitudinal studies of the gut microbiomes of twins aged 1-36 months living in Malawi who are healthy, or who are concordant or discordant for severe forms of malnutrition (e.g., kwashiorkor). We are addressing the following questions: Are there identifiable configurations of the gut microbiome associated with severe forms of malnutrition? How is the microbiota/microbiome reconfigured with a Ready to Use Therapeutic Food (RUTF) intervention and does it persist after cessation of RUTF? If the configured state does not persist after withdrawal of RUTF, does this mean that in the absence of longer-term nutritional support, lingering abnormalities in the metabolic activities contribute to persistent physiological abnormalities in the human host? We have recently shown that it is possible to efficiently transplant the microbial community present in frozen human fecal samples into germ-free (GF) mice and to transmit the engrafted microbiota from mothers to their offspring. With this capability, I propose two aims for this NRSA application. Aim 1. Use gnotobiotic mice, colonized at 6 weeks of age with de-identified fecal microbiota already collected from several sets of monozygotic twins discordant for kwashiorkor (1 healthy/ 1 malnourished) as well as their mothers' microbiota. Recipients will be fed a macro- and micronutrient deficient Malawi diet, or a control nutritionally 'sufficient' diet. I will follow their responses to mucosal vaccination with cholera toxin and ovalbumin (a model mucosal adjuvant/antigen) using antigen-specific ELISA. I will define their gut mucosal barrier function by serum LPS assays, lactulose/mannitol absorption assays, histo- and immunohistochemical assays of gut morphology and immune cell populations (exploring whether they have features of tropical enteropathy), plus functional genomic studies of gut gene expression. I will perform time series metagenomic studies on their fecal microbiomes (sequencing bacterial 16S rRNA genes, total community DNA, and expressed mRNAs). Aim 2. Assess the role of maternal nutritional and microbiota 'status' on the vaccine responses of their offspring by colonizing pregnant female GF mice with fecal samples from twins discordant for kwashiorkor and their mothers. Mothers will be maintained on either a Malawi or nutrient- sufficient control diet prior to, during and after pregnancy; their offspring will be weaned onto nutrient- deficient or -sufficient diets and subjected to the same vaccination protocols and analyses as described in Aim 1. These experiments should help identify biomarkers of malnutrition and vaccine responsiveness.
PUBLIC HEALTH RELEVANCE: Tragically, malnutrition is the leading cause of childhood death worldwide. To understand why malnourished children fail to respond to potentially life-saving vaccines, we are using gnotobiotic mice, colonized with the gut microbial communities harvested from monozygotic twins living in Malawi who are discordant for severe malnutrition, in order to characterize responses to oral vaccination as a function of diet and gut microbial community structure, with the expectation that translation of information gleaned from this mouse model will provide new mechanistic insights and therapeutic strategies for enhancing vaccine responses in vulnerable pediatric populations.
描述(由申请人提供):营养不良每年在全世界造成数百万儿童死亡。他们的发病率和死亡率大部分是感染的结果,包括肠道病原体引起的感染。由于无法解释的疫苗失败,在某些人群中阻止这些感染的努力受到限制。我假设营养不良,肠道微生物组和免疫系统之间存在相互关系,与疫苗反应性有因果关系,并且这些相互关系可以使用“人源化”gnotobiotic小鼠进行信息探测。我们的实验室正在对生活在马拉维的1-36个月大的双胞胎的肠道微生物组进行纵向研究,这些双胞胎是健康的,或者是严重营养不良的一致或不一致(例如,夸希奥科病)。我们正在解决以下问题:是否存在与严重营养不良相关的肠道微生物组的可识别配置?微生物群/微生物群是如何通过即食治疗食品(RUTF)干预重新配置的,以及在RUTF停止后是否持续存在?如果配置状态在RUTF停药后不持续,这是否意味着在缺乏长期营养支持的情况下,代谢活动的持续异常会导致人类宿主持续的生理异常?我们最近已经证明,有可能将冷冻人粪便样本中存在的微生物群落有效地移植到无菌(GF)小鼠中,并将移植的微生物群从母亲传给后代。有了这个能力,我提出了两个目标,这个NRSA应用程序。目标1.使用在6周龄时定植有去识别粪便微生物群的gnotobiotic小鼠,所述去识别粪便微生物群已经从几组与夸希奥科病不一致的单卵双胞胎(1个健康/ 1个营养不良)以及它们母亲的微生物群中收集。接受者将被喂食缺乏宏量和微量营养素的马拉维饮食,或营养“充足”的对照饮食。我将使用抗原特异性ELISA跟踪它们对霍乱毒素和卵清蛋白(一种模型粘膜佐剂/抗原)粘膜接种的反应。我将通过血清LPS测定、乳果糖/甘露醇吸收测定、肠道形态学和免疫细胞群的组织学和免疫组织化学测定(探索它们是否具有热带肠病的特征)以及肠道基因表达的功能基因组学研究来定义它们的肠道粘膜屏障功能。我将对他们的粪便微生物组进行时间序列宏基因组学研究(测序细菌16 S rRNA基因,总群落DNA和表达的mRNA)。目标二。评估母体营养和微生物群“状态”对其后代疫苗应答的作用,方法是用来自夸希奥科病及其母亲不一致的双胞胎的粪便样本定殖妊娠雌性GF小鼠。母亲在怀孕前、怀孕期间和怀孕后将保持马拉维或营养充足的对照饮食;其后代将断奶,改用营养不足或营养充足的饮食,并接受与目标1所述相同的疫苗接种方案和分析。这些实验应该有助于确定营养不良和疫苗反应的生物标志物。
公共卫生相关性:可悲的是,营养不良是全球儿童死亡的主要原因。为了理解为什么营养不良的儿童无法对可能挽救生命的疫苗产生反应,我们正在使用知菌小鼠,这些小鼠的肠道微生物群落是从生活在马拉维的严重营养不良不一致的同卵双胞胎中采集的,以描述对口服疫苗的反应作为饮食和肠道微生物群落结构的函数,期望从该小鼠模型中收集的信息的翻译将提供新的机制见解和治疗策略,用于增强脆弱儿科群体的疫苗应答。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Leon Kau其他文献
Andrew Leon Kau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Leon Kau', 18)}}的其他基金
Breathprinting as a window into gut microbiome chemoecology
呼吸印迹是了解肠道微生物组化学生态学的窗口
- 批准号:
10512356 - 财政年份:2022
- 资助金额:
$ 5.68万 - 项目类别:
Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections
利用抗体反应预防和治疗尿路感染
- 批准号:
10523527 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections
利用抗体反应预防和治疗尿路感染
- 批准号:
10344461 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
Microbial Origin of Breath Volatile Metabolites
呼吸挥发性代谢物的微生物来源
- 批准号:
10171781 - 财政年份:2020
- 资助金额:
$ 5.68万 - 项目类别:
Microbial Origin of Breath Volatile Metabolites
呼吸挥发性代谢物的微生物来源
- 批准号:
10043038 - 财政年份:2020
- 资助金额:
$ 5.68万 - 项目类别:
THE MICROBIOTA AND MUCOSAL IMMUNE RESPONSES IN THE DEVELOPMENT OF ASTHMA
哮喘发生过程中的微生物群和粘膜免疫反应
- 批准号:
9211283 - 财政年份:2015
- 资助金额:
$ 5.68万 - 项目类别:
The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
- 批准号:
8309675 - 财政年份:2011
- 资助金额:
$ 5.68万 - 项目类别:
The human gut microbiome, malnutrition and vaccine responses
人类肠道微生物组、营养不良和疫苗反应
- 批准号:
8469030 - 财政年份:2011
- 资助金额:
$ 5.68万 - 项目类别:
相似海外基金
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10458553 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10220588 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
Restoring age-dependent vaccine unresponsiveness by a novel ASP-1 adjuvant combination
通过新型 ASP-1 佐剂组合恢复年龄依赖性疫苗无反应
- 批准号:
10620718 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10415762 - 财政年份:2021
- 资助金额:
$ 5.68万 - 项目类别:
Dissecting the mechanism of age-specific adjuvant synergy in vitro and in vivo
剖析年龄特异性佐剂体外和体内协同作用的机制
- 批准号:
9108575 - 财政年份:2016
- 资助金额:
$ 5.68万 - 项目类别:
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
CoVPN 3005:两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性 - LC 3
- 批准号:
10570739 - 财政年份:2006
- 资助金额:
$ 5.68万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10686595 - 财政年份:2006
- 资助金额:
$ 5.68万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - 两种 SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成年人的功效、免疫原性和安全性
- 批准号:
10581414 - 财政年份:2006
- 资助金额:
$ 5.68万 - 项目类别:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
CoVPN 3005 - SARS-CoV-2 重组蛋白疫苗与佐剂对 18 岁及以上成人的功效、免疫原性和安全性
- 批准号:
10579557 - 财政年份:2006
- 资助金额:
$ 5.68万 - 项目类别: